Abstract
Objective
Treatment options are still limited in patients with cisplatin-refractory and multiply relapsed germ cell tumors. We evaluated the efficacy and tolerability of lenalidomide within a compassionate use concept.
Patients and methods
Four patients multiply relapsed after platin-based chemotherapies without any further standard treatment option received 25 mg lenalidomide orally on days 1–21 of a 28-day cycle.
Results
All four patients were pretreated with a median number of seven lines of previous chemotherapy (range 4–8), all including platin-based high-dose chemotherapy. After 4 weeks of lenalidomide treatment all patients had progressive disease with increase in serum tumor markers and progression in computed tomography. Median survival time was 8 weeks (range 5–17). The toxicity profile was favorable. No severe toxicities related to lenalidomide occurred in these patients.
Conclusion
Lenalidomide was well tolerated and showed efficacy in heavily pretreated patients with cisplatin-refractory and multiply relapsed germ cell tumors.
This is a preview of subscription content, log in via an institution to check access.
References
Beyer J, Kingreen D, Krause M et al (1997) Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 79:161–168. doi:10.1002/(SICI)1097-0142(19970101)79:1<161:AID-CNCR23>3.0.CO;2-1
Bokemeyer C, Beyer J, Metzner B et al (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7:31–34
Bokemeyer C, Gerl A, Schoffski P et al (1999) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17:512–516
Einhorn LH (1999) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8:1777–1781
Einhorn LH, Stender MJ, Williams SD (1999) Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 17:509–511
Fizazi K, Culine S, Chen I (2004) Oxaliplatin in non-seminomatous germ-cell tumors. Ann Oncol 15:1295. doi:10.1093/annonc/mdh307
Hartmann JT, Kanz L, Bokemeyer C (1999) Diagnosis and treatment of patients with testicular germ cell cancer. Drugs 58:257–281. doi:10.2165/00003495-199958020-00004
Kollmannsberger C, Rick O, Derigs H-G et al (2002) Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 20:2031–2037. doi:10.1200/JCO.2002.08.050
Miller JC, Einhorn LR (1990) Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 17:36–39
Rick O, Braun T, Siegert W, Beyer J (2006) Activity of thalidomide in patients with platinum-refractory germ-cell tumors. Eur J Cancer 42:1775–1779. doi:10.1016/j.ejca.2006.03.013
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s00432-009-0697-y
Rights and permissions
About this article
Cite this article
Oechsle, K., Bokemeyer, C. & Honecker, F. Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors. J Cancer Res Clin Oncol 136, 165–167 (2010). https://doi.org/10.1007/s00432-009-0677-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-009-0677-2